MedTech VC Fund
PICTURE ISTOCK
| Currency | USD |
| Management fees | 2% |
| ISIN | LU2377360529, LU2401175760 |
| Impact | This investment will help save lives and safeguard medical progress. |
Business Case
The MedTech Fund offers access to the Shifamed portfolio companies by predominantly
investing in current and newly created companies, all of which focus on attractive high growth markets such as cardiovascular, ophthalmology, digital health and AI.
These companies implement a fast-follower strategy to expedite value creation. Starting with a large, clearly defined unmet clinical need and a competitive landscape of promising first-generation platforms, Shifamed’s approach has the potential to deliver significant value to the market and investors by leveraging established regulatory and reimbursement pathways.
The development model, infrastructure, and depth of core competencies are designed for
speed and optimized for early exits, proven with six successful exits to strategic partners,
all with an expedited time to sale compared to industry average.
Investment Opportunity
-
Demographics
Ageing population is leading to major structural growth for cardio-vascular and eye-related issues -
Market
Making up 10% of global GDP, the healthcare sector is a huge market with enormous potential for optimization -
Digitisation
The healthcare sector is at the start of its digitization journey and together with the increased use of sensors is set for rapid growth -
Impact
With this investment you help to save lives and safeguard medical progress -
Returns
Our fund targets three to five-fold returns for each opportunity in a five-year timeframe* -
Risk
Our fund aims to minimize risk compared to standard venture capital investments
Investment Benefits
- 6 Exits out of 6, to strategic partners
- 4.7 x Solid steady returns on average
- De-risked opportunity compared to similar growth investments
- < 5Y Expeditated time to sale on average
Product data
| Product | MedTech VC Fund |
| Currency | USD |
| Management fees | 2% |
| ISIN | LU2377360529, LU2401175760 |
| Impact | This investment will help save lives and safeguard medical progress. |
| Authorized for public distribution | CH, MEA |
| Investment manager | Picard Angst |
| Custodian bank | UBS |
| Management company | Notz Stucki (LU) |
| Fund domicile | Luxemburg |
Your contacts
This content has been prepared by Picard Angst AG and is only a summary of the main features of the product and not a complete presentation and has been prepared solely for information purposes for use by the recipient for the duration of the subscription period. The information provided is valid only for this period. The information in this page does not constitute financial research and does not meet all legal requirements to ensure the impartiality of financial research and is not subject to any prohibition on trading prior to the publication of financial research. This page does not constitute an offer or invitation to buy or sell financial instruments. It is intended for informational purposes only. Given that an investment product can be a complex financial product, the decision to invest should therefore always be based on a consultation with a bank advisor. The information provided on this page on opportunities and risks is no substitute for the information provided by your investment advisor, which is always indispensable before concluding a transaction. Only those who are clear about the opportunities and risks of the transaction to be concluded and who are economically able to bear the losses that may occur should enter into such transactions.